3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
53
Colonic Neoplasms
11
Neoplasms
10
Rectal Neoplasms
9
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Gastrointestinal Neoplasms
4
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Brain Neoplasms
2
Urinary Bladder Neoplasms
1
Unresectable Metastatic Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ras-mutated Metastatic Colorectal Cancer
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroendocrine Tumors
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Injections
24
pembrolizumab
13
toripalimab
12
tislelizumab
9
Gemcitabine
7
Cisplatin
7
Carboplatin
6
atezolizumab
5
Nivolumab
5
Irinotecan
5
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
trastuzumab deruxtecan
3
spartalizumab
3
cediranib
3
Paclitaxel
3
PM 01183
3
Capecitabine
3
sintilimab
2
olaparib
2
lenvatinib
2
glumetinib
2
camrelizumab
2
apatinib
2
Therapeutics
2
Midazolam
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Tumor
×
IFL protocol
×
Clear all
NCT05147350
2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1
Terminated
38 enrolled
17 charts